Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Geron Corporation

Market Cap 738M 637M 587M 550M 1.03B 70.12B 1.05B 6.93B 2.7B 34.13B 2.77B 2.71B 118B P/E Ratio 2026 *
-57.5x
P/E Ratio 2027 * 17.7x
Enterprise Value 717M 619M 570M 534M 1B 68.13B 1.02B 6.74B 2.63B 33.16B 2.69B 2.63B 115B EV / Sales 2026 *
3.07x
EV / Sales 2027 * 1.71x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+0.88%
1 week-1.71%
Current month-8.00%
1 month-18.44%
3 months-27.22%
6 months-15.44%
Current year-12.88%
1 week 1.08
Extreme 1.08
1.22
1 month 1.08
Extreme 1.08
1.4
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 06/08/2025
Director of Finance/CFO 59 24/09/2023
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 76 20/05/2010
Director/Board Member 72 27/09/2012
Director/Board Member 55 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

220,000 0.0343%
05-19Free

Director

220,000 0.0343%
05-19Free

Chairman

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%-1.71%-23.84%-64.72% 738M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.71%+1.71%+22.57%+87.63% 21.45B
Weighted average by Cap. +1.72%+2.35%+31.85%+99.00%

Financials

2026 *2027 *
Net sales 234M 202M 186M 174M 326M 22.22B 331M 2.2B 856M 10.81B 877M 859M 37.44B 333M 288M 265M 248M 465M 31.66B 472M 3.13B 1.22B 15.41B 1.25B 1.22B 53.37B
Net income -13.95M -12.05M -11.11M -10.4M -19.48M -1.33B -19.78M -131M -51.13M -646M -52.37M -51.25M -2.24B 46.55M 40.2M 37.05M 34.68M 64.99M 4.42B 66M 437M 171M 2.15B 175M 171M 7.46B
Net Debt -20.97M -18.11M -16.69M -15.62M -29.28M -1.99B -29.73M -197M -76.83M -970M -78.7M -77.02M -3.36B -169M -146M -135M -126M -236M -16.06B -240M -1.59B -619M -7.82B -634M -621M -27.07B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
12/06/26 1.150 $ +0.88% 8,110,734
11/06/26 1.140 $ +3.64% 31,746,036
10/06/26 1.100 $ -1.79% 14,737,296
09/06/26 1.120 $ -0.88% 13,609,303
08/06/26 1.130 $ -3.42% 11,184,588
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.150USD
Average target price
3.400USD
Spread / Average Target
+195.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!